{"id": "1355998049236082691", "creation": 1612130102.0, "user_id": "31484145", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 1, "like_count": 5, "quote_count": 0}}, "text": ".@Novavax Reports Varying Success vs. #COVID19 Variants\n\nNovavax electrified investors by announcing that its COVID-19 vaccine NVX-CoV2373 showed efficacy of 89.3% in the company\u2019s first analysis. Read more: https://t.co/ITLdXti3Ne #vaccine #coronavirus #SARCoV2 https://t.co/NBQQ0nabQr", "first_save": 1634559108.199414, "hashtags": ["#COVID19", "#VACCINE", "#CORONAVIRUS", "#SARCOV2"]}